2025 Q3 -tulosraportti
23 päivää sitten36 min
Tarjoustasot
Spotlight Stock Market DK
Määrä
Osto
0
Myynti
Määrä
0
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
-VWAP
Alin
-Vaihto ()
VWAP
Ylin
-Alin
-Vaihto ()
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 19.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 1.12. | |
| 2025 Q2 -tulosraportti | 28.8. | |
| 2025 Q1 -tulosraportti | 25.4. | |
| 2024 Q4 -tulosraportti | 27.2. | |
| 2024 Q3 -tulosraportti | 21.11.2024 |
Datan lähde: Quartr, FactSet
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·23 t sittenWhat do you think this stock will be worth in a year?
·1 t sitten · MuokattuMerry Christmas, now we all own shares in Curasight because we believe it works. One can take the number of potential patients globally x assumed price of treatment. Then we have a best scenario for revenue - if we then assume the company can be sold in a scenario with a multiplication factor based on previous similar transactions and divide by the number of shares, it looks like this: Conservative Best-case 12 mia. kr. Kurs 260kr. Optimistic Best-case / high-end 50 mia. kr. Kurs 1.087 kr. But - that won't happen tomorrow - and it is assumed everything works as it should!
·23 t sittenNothing short of exciting times ahead. However, it's important to remember that trees rarely grow into the sky. I hope that the last aggressive 'run' hasn't attracted too much hype from people who didn't quite manage to fully understand the case. If you've entered it, you probably shouldn't believe it will be at 20 in 2 weeks - and the chance that it could fall back a few points is definitely present. 2026 looks incredibly exciting though, so whether you just bought at 9 or 13 right now might prove irrelevant in 12 months. I just hope people think carefully over the next few days/weeks, if it suddenly completely loses momentum and drops back. There's also the financing, Fenja, which is haunting. I had actually hoped that they would elaborate more on that, if one is to nitpick. For what thoughts have been given to 'teaming' up with Fenja, which is notoriously a sign of being a bit desperate? And which can convert (i.e., uncertainty about a coming dilution will haunt...?). Not to mention the fact that it's an expensive loan, whether used or not. I miss a bit of communication from management here - because yes, they have "secured" that they can run until 2026, but at what cost have they secured it and why have they done what they have done? It feels, all things considered, like a signal that money from Curium is not exactly coming in Q1 2026.
·21 t sittenThe Fenja agreement should not be assessed in isolation, but together with: ✔ The Curium agreement (up to 69 million USD in milestones) ✔ uTRACE in Phase II ✔ uTREAT in clinic ✔ significantly reduced funding risk Together, this means: - Curasight is not forced to sell itself cheaply. which indicates: - Strengthened negotiation position - Increased upside for existing shareholders I fully agree that Curium does not have milestone payments in Q12026 and probably not until late Q3 2026, depending on how phase II of uTRACE progresses. Unfortunately, we do not know the details of the agreement. But precisely for this reason, Curasight needs further financing for operations in Q12026 and until the milestone payments. How is Fenja interpreted in a Curasight context? Fenja involved = 🔹 The company is assessed as viable 🔹 Not yet equity-financed on attractive terms.- ·2 päivää sittenSo far, the model appears to hold. It has been taken into account that the stock is relatively illiquid and the low price for 6 months. These 2 factors significantly increase volatility, but do not affect the case itself. CHECKLIST – with price indicators (updated after BioStock / CEO statements). Starting point: price approx. 10 DKK) 🔴 STEP 1 – SURVIVAL (binary) Status: ✅ FULFILLED ✅ First Patient Dosed (FPD) ✅ No reported safety-issues ✅ Study officially active Market interpretation: The existential risk has been removed. uTREAT is now a clinical asset. 📈 Price indicator: 11–14 DKK (+20–40 %) 🟠 STEP 2 – TARGET ENGAGEMENT Status: 🟢 VERY STRONGLY INDICATED – awaiting clinical imaging data 🟢 uPAR-target clinically validated via uTRACE (Phase II) 🟢 94 % of high-grade gliomas are uPAR-positive (broad addressable population) 🟡 Clinical tumor uptake / biodistribution lacks public reporting Update: The very high uPAR prevalence reduces the risk of biological failure and strengthens the expectation of target engagement in a therapeutic setting. 📈 Price indicator upon confirmation: 18–30 DKK We should receive readouts on FPD shortly, according to statements from the CSO Readouts vs. Interim data: Topic, Readout, Interim data Number of patients: 1, 2–6 Timing: Days–weeks, Months Imaging: Yes, Yes Dosimetry: Early, Consistent Effect: No /very early, Yes (indicative) Steps fulfilled: Step 2 (+ possibly 3-light), Step 3
- ·2 päivää sittenQuite a great day. If one can then top that with some data that just marginally surprises positively today or tomorrow, then one isn't even done seeing it rise. Congratulations to CURAS on a great half-year, congratulations to the shareholders and one can only cross one's fingers that this fantastic technology can come in and establish itself more and more as a promising and realistic option for future treatments.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q3 -tulosraportti
23 päivää sitten36 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·23 t sittenWhat do you think this stock will be worth in a year?·1 t sitten · MuokattuMerry Christmas, now we all own shares in Curasight because we believe it works. One can take the number of potential patients globally x assumed price of treatment. Then we have a best scenario for revenue - if we then assume the company can be sold in a scenario with a multiplication factor based on previous similar transactions and divide by the number of shares, it looks like this: Conservative Best-case 12 mia. kr. Kurs 260kr. Optimistic Best-case / high-end 50 mia. kr. Kurs 1.087 kr. But - that won't happen tomorrow - and it is assumed everything works as it should!
- ·23 t sittenNothing short of exciting times ahead. However, it's important to remember that trees rarely grow into the sky. I hope that the last aggressive 'run' hasn't attracted too much hype from people who didn't quite manage to fully understand the case. If you've entered it, you probably shouldn't believe it will be at 20 in 2 weeks - and the chance that it could fall back a few points is definitely present. 2026 looks incredibly exciting though, so whether you just bought at 9 or 13 right now might prove irrelevant in 12 months. I just hope people think carefully over the next few days/weeks, if it suddenly completely loses momentum and drops back. There's also the financing, Fenja, which is haunting. I had actually hoped that they would elaborate more on that, if one is to nitpick. For what thoughts have been given to 'teaming' up with Fenja, which is notoriously a sign of being a bit desperate? And which can convert (i.e., uncertainty about a coming dilution will haunt...?). Not to mention the fact that it's an expensive loan, whether used or not. I miss a bit of communication from management here - because yes, they have "secured" that they can run until 2026, but at what cost have they secured it and why have they done what they have done? It feels, all things considered, like a signal that money from Curium is not exactly coming in Q1 2026.·21 t sittenThe Fenja agreement should not be assessed in isolation, but together with: ✔ The Curium agreement (up to 69 million USD in milestones) ✔ uTRACE in Phase II ✔ uTREAT in clinic ✔ significantly reduced funding risk Together, this means: - Curasight is not forced to sell itself cheaply. which indicates: - Strengthened negotiation position - Increased upside for existing shareholders I fully agree that Curium does not have milestone payments in Q12026 and probably not until late Q3 2026, depending on how phase II of uTRACE progresses. Unfortunately, we do not know the details of the agreement. But precisely for this reason, Curasight needs further financing for operations in Q12026 and until the milestone payments. How is Fenja interpreted in a Curasight context? Fenja involved = 🔹 The company is assessed as viable 🔹 Not yet equity-financed on attractive terms.
- ·2 päivää sittenSo far, the model appears to hold. It has been taken into account that the stock is relatively illiquid and the low price for 6 months. These 2 factors significantly increase volatility, but do not affect the case itself. CHECKLIST – with price indicators (updated after BioStock / CEO statements). Starting point: price approx. 10 DKK) 🔴 STEP 1 – SURVIVAL (binary) Status: ✅ FULFILLED ✅ First Patient Dosed (FPD) ✅ No reported safety-issues ✅ Study officially active Market interpretation: The existential risk has been removed. uTREAT is now a clinical asset. 📈 Price indicator: 11–14 DKK (+20–40 %) 🟠 STEP 2 – TARGET ENGAGEMENT Status: 🟢 VERY STRONGLY INDICATED – awaiting clinical imaging data 🟢 uPAR-target clinically validated via uTRACE (Phase II) 🟢 94 % of high-grade gliomas are uPAR-positive (broad addressable population) 🟡 Clinical tumor uptake / biodistribution lacks public reporting Update: The very high uPAR prevalence reduces the risk of biological failure and strengthens the expectation of target engagement in a therapeutic setting. 📈 Price indicator upon confirmation: 18–30 DKK We should receive readouts on FPD shortly, according to statements from the CSO Readouts vs. Interim data: Topic, Readout, Interim data Number of patients: 1, 2–6 Timing: Days–weeks, Months Imaging: Yes, Yes Dosimetry: Early, Consistent Effect: No /very early, Yes (indicative) Steps fulfilled: Step 2 (+ possibly 3-light), Step 3
- ·2 päivää sittenQuite a great day. If one can then top that with some data that just marginally surprises positively today or tomorrow, then one isn't even done seeing it rise. Congratulations to CURAS on a great half-year, congratulations to the shareholders and one can only cross one's fingers that this fantastic technology can come in and establish itself more and more as a promising and realistic option for future treatments.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Spotlight Stock Market DK
Määrä
Osto
0
Myynti
Määrä
0
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
-VWAP
Alin
-Vaihto ()
VWAP
Ylin
-Alin
-Vaihto ()
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 19.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 1.12. | |
| 2025 Q2 -tulosraportti | 28.8. | |
| 2025 Q1 -tulosraportti | 25.4. | |
| 2024 Q4 -tulosraportti | 27.2. | |
| 2024 Q3 -tulosraportti | 21.11.2024 |
Datan lähde: Quartr, FactSet
2025 Q3 -tulosraportti
23 päivää sitten36 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 19.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 1.12. | |
| 2025 Q2 -tulosraportti | 28.8. | |
| 2025 Q1 -tulosraportti | 25.4. | |
| 2024 Q4 -tulosraportti | 27.2. | |
| 2024 Q3 -tulosraportti | 21.11.2024 |
Datan lähde: Quartr, FactSet
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·23 t sittenWhat do you think this stock will be worth in a year?·1 t sitten · MuokattuMerry Christmas, now we all own shares in Curasight because we believe it works. One can take the number of potential patients globally x assumed price of treatment. Then we have a best scenario for revenue - if we then assume the company can be sold in a scenario with a multiplication factor based on previous similar transactions and divide by the number of shares, it looks like this: Conservative Best-case 12 mia. kr. Kurs 260kr. Optimistic Best-case / high-end 50 mia. kr. Kurs 1.087 kr. But - that won't happen tomorrow - and it is assumed everything works as it should!
- ·23 t sittenNothing short of exciting times ahead. However, it's important to remember that trees rarely grow into the sky. I hope that the last aggressive 'run' hasn't attracted too much hype from people who didn't quite manage to fully understand the case. If you've entered it, you probably shouldn't believe it will be at 20 in 2 weeks - and the chance that it could fall back a few points is definitely present. 2026 looks incredibly exciting though, so whether you just bought at 9 or 13 right now might prove irrelevant in 12 months. I just hope people think carefully over the next few days/weeks, if it suddenly completely loses momentum and drops back. There's also the financing, Fenja, which is haunting. I had actually hoped that they would elaborate more on that, if one is to nitpick. For what thoughts have been given to 'teaming' up with Fenja, which is notoriously a sign of being a bit desperate? And which can convert (i.e., uncertainty about a coming dilution will haunt...?). Not to mention the fact that it's an expensive loan, whether used or not. I miss a bit of communication from management here - because yes, they have "secured" that they can run until 2026, but at what cost have they secured it and why have they done what they have done? It feels, all things considered, like a signal that money from Curium is not exactly coming in Q1 2026.·21 t sittenThe Fenja agreement should not be assessed in isolation, but together with: ✔ The Curium agreement (up to 69 million USD in milestones) ✔ uTRACE in Phase II ✔ uTREAT in clinic ✔ significantly reduced funding risk Together, this means: - Curasight is not forced to sell itself cheaply. which indicates: - Strengthened negotiation position - Increased upside for existing shareholders I fully agree that Curium does not have milestone payments in Q12026 and probably not until late Q3 2026, depending on how phase II of uTRACE progresses. Unfortunately, we do not know the details of the agreement. But precisely for this reason, Curasight needs further financing for operations in Q12026 and until the milestone payments. How is Fenja interpreted in a Curasight context? Fenja involved = 🔹 The company is assessed as viable 🔹 Not yet equity-financed on attractive terms.
- ·2 päivää sittenSo far, the model appears to hold. It has been taken into account that the stock is relatively illiquid and the low price for 6 months. These 2 factors significantly increase volatility, but do not affect the case itself. CHECKLIST – with price indicators (updated after BioStock / CEO statements). Starting point: price approx. 10 DKK) 🔴 STEP 1 – SURVIVAL (binary) Status: ✅ FULFILLED ✅ First Patient Dosed (FPD) ✅ No reported safety-issues ✅ Study officially active Market interpretation: The existential risk has been removed. uTREAT is now a clinical asset. 📈 Price indicator: 11–14 DKK (+20–40 %) 🟠 STEP 2 – TARGET ENGAGEMENT Status: 🟢 VERY STRONGLY INDICATED – awaiting clinical imaging data 🟢 uPAR-target clinically validated via uTRACE (Phase II) 🟢 94 % of high-grade gliomas are uPAR-positive (broad addressable population) 🟡 Clinical tumor uptake / biodistribution lacks public reporting Update: The very high uPAR prevalence reduces the risk of biological failure and strengthens the expectation of target engagement in a therapeutic setting. 📈 Price indicator upon confirmation: 18–30 DKK We should receive readouts on FPD shortly, according to statements from the CSO Readouts vs. Interim data: Topic, Readout, Interim data Number of patients: 1, 2–6 Timing: Days–weeks, Months Imaging: Yes, Yes Dosimetry: Early, Consistent Effect: No /very early, Yes (indicative) Steps fulfilled: Step 2 (+ possibly 3-light), Step 3
- ·2 päivää sittenQuite a great day. If one can then top that with some data that just marginally surprises positively today or tomorrow, then one isn't even done seeing it rise. Congratulations to CURAS on a great half-year, congratulations to the shareholders and one can only cross one's fingers that this fantastic technology can come in and establish itself more and more as a promising and realistic option for future treatments.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Spotlight Stock Market DK
Määrä
Osto
0
Myynti
Määrä
0
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
-VWAP
Alin
-Vaihto ()
VWAP
Ylin
-Alin
-Vaihto ()
Välittäjätilasto
Dataa ei löytynyt